Beta Bionics, Inc.
Price Action
Technical Summary
CONSOLIDATINGBeta Bionics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 69), indicating performance broadly in line with the market. Earnings growth of 47% provides fundamental context to the price action. However, price is extended 40% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $13.97 | +20.41% | ABOVE |
| 50 SMA | $12.03 | +39.85% | ABOVE |
| 100 SMA | $11.90 | +41.34% | ABOVE |
| 150 SMA | $16.53 | +1.76% | ABOVE |
| 200 SMA | $18.30 | -8.08% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is BBNX in an uptrend right now?
BBNX has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is BBNX overbought or oversold?
BBNX's RSI (14) is 71. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is BBNX outperforming the market?
BBNX has a Relative Strength (RS) Rating of 69 out of 99. BBNX is performing about average compared to the market.
Where is BBNX in its 52-week range?
BBNX is trading at $16.82, which is 51% of its 52-week high ($32.71) and 34% above its 52-week low ($8.80).
How volatile is BBNX?
BBNX has a Beta of 1.36 and 52-week volatility of 82%. It's more volatile than the S&P 500 - expect bigger swings.